Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23816515 | 1.00 | CRBN (0.45) | CRBNDDB1HRH3OPRM1OPRL1 | |
| SCHEMBL24834126 | 0.91 | CRBN (0.47) | CRBNDDB1HRH3GPR119 | |
| SCHEMBL23984143 | 0.83 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL29990545 | 0.83 | CRBN (0.45) | CRBNDDB1HRH3OPRM1OPRL1 | |
| SCHEMBL25074151 | 0.83 | CRBN (0.45) | CRBNDDB1HRH3OPRM1OPRL1 | |
| SCHEMBL30441872 | 0.82 | CRBN (0.45) | CRBNDDB1HRH3 | |
| SCHEMBL25198430 | 0.82 | CRBN (0.45) | CRBNDDB1HRH3 | |
| SCHEMBL22119849 | 0.81 | CRBN (0.51) | CRBNDDB1HRH3OPRM1OPRL1 | |
| SCHEMBL30288900 | 0.81 | CRBN (0.51) | CRBNDDB1HRH3OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL28627283 | 0.80 | CRBN (0.50) | CRBNDDB1HRH3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4457230-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118414336-A | Degradation of Bruton Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023023255-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-115335376-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitor with E3 ligase ligand and methods of use thereof | 百济神州有限公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |